Juan Shen, PhD

Merck & Co., Inc.

Poster(s):

• 1511 - Nemtabrutinib in Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Phase 3 BELLWAVE-011 Study